TWI674904B - 用於免疫療法的化合物及組合物 - Google Patents

用於免疫療法的化合物及組合物 Download PDF

Info

Publication number
TWI674904B
TWI674904B TW104100854A TW104100854A TWI674904B TW I674904 B TWI674904 B TW I674904B TW 104100854 A TW104100854 A TW 104100854A TW 104100854 A TW104100854 A TW 104100854A TW I674904 B TWI674904 B TW I674904B
Authority
TW
Taiwan
Prior art keywords
alkyl
cancer
imidazo
aryl
amino
Prior art date
Application number
TW104100854A
Other languages
English (en)
Chinese (zh)
Other versions
TW201613648A (en
Inventor
立新 李
Original Assignee
大陸商上海博笛生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410011362.0A external-priority patent/CN104861064A/zh
Priority claimed from CN201410011324.5A external-priority patent/CN104861067A/zh
Priority claimed from CN201410011262.8A external-priority patent/CN104861063A/zh
Application filed by 大陸商上海博笛生物科技有限公司 filed Critical 大陸商上海博笛生物科技有限公司
Publication of TW201613648A publication Critical patent/TW201613648A/zh
Application granted granted Critical
Publication of TWI674904B publication Critical patent/TWI674904B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW104100854A 2014-01-10 2015-01-09 用於免疫療法的化合物及組合物 TWI674904B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201410011362.0A CN104861064A (zh) 2014-01-10 2014-01-10 靶向表达egfr的肿瘤的化合物和组合物
??201410011262.8 2014-01-10
CN201410011324.5A CN104861067A (zh) 2014-01-10 2014-01-10 用于免疫疗法的化合物和组合物
CN201410011262.8A CN104861063A (zh) 2014-01-10 2014-01-10 靶向her2阳性肿瘤的化合物和组合物
??201410011324.5 2014-01-10
??201410011362.0 2014-01-10

Publications (2)

Publication Number Publication Date
TW201613648A TW201613648A (en) 2016-04-16
TWI674904B true TWI674904B (zh) 2019-10-21

Family

ID=53523554

Family Applications (3)

Application Number Title Priority Date Filing Date
TW104100854A TWI674904B (zh) 2014-01-10 2015-01-09 用於免疫療法的化合物及組合物
TW104100852A TWI691337B (zh) 2014-01-10 2015-01-09 靶向表現ｅｇｆｒ的腫瘤的化合物及組合物
TW104100853A TWI691338B (zh) 2014-01-10 2015-01-09 靶向ｈｅｒ２陽性腫瘤的化合物及組合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW104100852A TWI691337B (zh) 2014-01-10 2015-01-09 靶向表現ｅｇｆｒ的腫瘤的化合物及組合物
TW104100853A TWI691338B (zh) 2014-01-10 2015-01-09 靶向ｈｅｒ２陽性腫瘤的化合物及組合物

Country Status (12)

Country Link
US (11) US10548985B2 (cg-RX-API-DMAC7.html)
EP (4) EP3092256B1 (cg-RX-API-DMAC7.html)
JP (5) JP2017502068A (cg-RX-API-DMAC7.html)
CN (6) CN105899539B (cg-RX-API-DMAC7.html)
AU (3) AU2015205755C1 (cg-RX-API-DMAC7.html)
CA (3) CA2936376A1 (cg-RX-API-DMAC7.html)
DK (1) DK3092256T3 (cg-RX-API-DMAC7.html)
ES (1) ES2916873T3 (cg-RX-API-DMAC7.html)
IL (3) IL246680A0 (cg-RX-API-DMAC7.html)
SG (3) SG11201605296SA (cg-RX-API-DMAC7.html)
TW (3) TWI674904B (cg-RX-API-DMAC7.html)
WO (3) WO2015103987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
SG11201605296SA (en) * 2014-01-10 2016-07-28 Birdie Biopharmaceuticals Inc Compounds and compositions for treating her2 positive tumors
DK3166976T3 (da) 2014-07-09 2022-04-11 Birdie Biopharmaceuticals Inc Anti-pd-l1-kombinationer til behandling af tumorer
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
MA44334A (fr) * 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CA3007311A1 (en) * 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Compositions of antibody construct-agonist conjugates and methods of use thereof
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) * 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) * 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
JOP20170053B1 (ar) 2016-03-02 2021-08-17 Eisai Randd Man Co Ltd مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
CN109843327B (zh) * 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
CN107773762B (zh) * 2016-08-31 2021-06-15 上海干云生物科技有限公司 基于pd-l1抗体偶联化疗药物的adc及其制备方法和应用
JP7206590B2 (ja) * 2016-10-28 2023-01-18 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
EP3554550A1 (en) * 2016-12-13 2019-10-23 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
EP4218824A3 (en) * 2017-04-14 2023-08-09 Bolt Biotherapeutics, Inc. Immunoconjugate synthesis method
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
US11517567B2 (en) * 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
EP3649142A4 (en) 2017-07-04 2021-09-01 Intocell, Inc. COMPOUNDS INCLUDING A CLIVABLE LOCATION AND THEIR USES
EP4257198A3 (en) 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
US11771764B2 (en) 2017-11-06 2023-10-03 Pfizer Inc. CD47 blockade with radiation therapy
EP3710059A1 (en) * 2017-11-14 2020-09-23 Dynavax Technologies Corporation Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
KR102436923B1 (ko) * 2018-01-26 2022-08-26 주식회사 엘지화학 광 감응기를 포함하는 블록 공중합체
CA3093110A1 (en) * 2018-03-03 2019-09-12 The University Of Tokyo Prodrug-type anticancer agent using cancer-specific enzymatic activity
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
TWI672637B (zh) * 2018-05-03 2019-09-21 長庚醫療財團法人林口長庚紀念醫院 自體免疫抗體免疫螢光影像型態識別方法
WO2019226977A1 (en) * 2018-05-25 2019-11-28 Primmune Therapeutics, Inc. Tlr7 agonists
CN109134654B (zh) * 2018-08-02 2021-08-03 广东药科大学 一种靶向egfr二聚化界面的单链抗体及其应用
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
FR3085952B1 (fr) * 2018-09-17 2020-10-30 Centre Nat Rech Scient Conjugue anticorps-medicament comprenant des derives de quinoline
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
BR112021012365A2 (pt) * 2019-01-03 2021-08-31 Intocell, Inc. Compostos que compreendem ligante clivável e usos dos mesmos
KR20210099658A (ko) * 2019-01-03 2021-08-12 주식회사 인투셀 절단가능 링커를 포함하는 화합물 및 이의 용도
CN113660957B (zh) * 2019-02-12 2024-12-13 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2020190731A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
AU2021300362A1 (en) 2020-07-01 2023-02-23 ARS Pharmaceuticals, Inc. Anti-ASGR1 antibody conjugates and uses thereof
CN116056725A (zh) * 2020-08-04 2023-05-02 蛋白科技先鋒 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途
CN116056710A (zh) * 2020-08-26 2023-05-02 博笛生物科技有限公司 用tlr激动剂治疗癌症
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
US20230373997A1 (en) * 2020-10-08 2023-11-23 Icahn School Of Medicine At Mount Sinai Imdq-peg-chol adjuvant and uses thereof
WO2022120014A1 (en) * 2020-12-04 2022-06-09 Macrogenics, Inc. Pharmaceutical compositions of a her2/neu antibody and use of the same
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
CA3211468A1 (en) * 2021-03-02 2022-09-09 The Research Foundation For The State University Of New York Tlr7 and tlr8 agonists for the treatment of cancer and/or infectious diseases
US20240181072A1 (en) * 2021-03-08 2024-06-06 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof
EP4397315A4 (en) 2021-08-30 2025-09-24 Toray Industries COMPOSITION TO IMPROVE IMMUNOGENICITY
WO2023032892A1 (ja) 2021-08-30 2023-03-09 東レ株式会社 免疫原性増強用組成物
CN118159285A (zh) 2021-09-16 2024-06-07 东丽株式会社 用于癌的治疗和/或预防的药品
WO2023086833A1 (en) 2021-11-09 2023-05-19 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
KR20250128394A (ko) 2022-11-30 2025-08-27 리제너론 파마슈티칼스 인코포레이티드 Tlr7 작용제 및 이의 항체-약물-접합체
WO2025015586A1 (en) * 2023-07-20 2025-01-23 Canwell Biotech Limited Drug conjugates of imidazoquinoline amine derivatives, compositions and methods thereof
WO2025240397A1 (en) * 2024-05-14 2025-11-20 The Research Foundation For The State University Of New York Tlr7 and tlr8 agonists and antibody-drug congjugates for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079924A1 (en) * 2006-12-22 2008-07-03 3M Innovative Properties Company Immune response modifier compositions and methods

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5789163A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5874218A (en) 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5853984A (en) 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US6465189B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
AU663053B2 (en) 1990-06-11 1995-09-28 Gilead Sciences, Inc. Nucleic acid ligands
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5226575A (en) 1991-11-21 1993-07-13 Scott Faust Pneumatic mortar dispenser with flex release
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US6608201B2 (en) 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5843732A (en) 1995-06-06 1998-12-01 Nexstar Pharmaceuticals, Inc. Method and apparatus for determining consensus secondary structures for nucleic acid sequences
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6605713B1 (en) 1996-08-30 2003-08-12 Jens Peter Furste Mirror-symmetrical selection and evolution of nucleic acids
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6403779B1 (en) 1999-01-08 2002-06-11 Isis Pharmaceuticals, Inc. Regioselective synthesis of 2′-O-modified nucleosides
US20030054360A1 (en) 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
KR20020012292A (ko) 1999-06-25 2002-02-15 제넨테크, 인크. 항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US20050020525A1 (en) 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
DE20014503U1 (de) 2000-08-22 2001-01-11 Siemens AG, 80333 München Fertigungsstraßenabschnitt
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2598144A1 (en) 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
DK1264603T3 (da) 2001-06-10 2010-04-26 Noxxon Pharma Ag Anvendelse af L-polynukleotider til in vivo-billeddannelse
AU2775402A (en) 2001-06-29 2003-01-02 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
WO2003094836A2 (en) 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040014779A1 (en) 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
BR0214407A (pt) 2001-11-27 2004-10-19 Anadys Pharmaceuticals Inc Compostos, composições farmacêuticas e método de modulação das imunoatividades da citocina
AU2002360733A1 (en) 2001-12-31 2003-07-24 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA(imn)PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003276131A1 (en) 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1413316A1 (en) 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
US7091214B2 (en) 2002-12-20 2006-08-15 3M Innovative Properties Co. Aryl substituted Imidazoquinolines
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
KR20050114211A (ko) 2003-01-09 2005-12-05 아리제케 파마슈티칼즈 인크. 폐 질환의 치료 방법
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
EP1592302A4 (en) 2003-02-13 2007-04-25 3M Innovative Properties Co METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
EP2100619B1 (en) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders
WO2006113909A2 (en) 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
WO2005032484A2 (en) 2003-10-03 2005-04-14 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
AU2004280143A1 (en) 2003-10-11 2005-04-21 Tekmira Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
ITMI20032121A1 (it) 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US20050239735A1 (en) 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
MXPA06011080A (es) 2004-03-26 2007-04-16 Astrazeneca Ab Compuesto de 8-oxoadenina 9-sustituido.
EP1776105A2 (en) * 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
CN101065151B (zh) * 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
AU2005304771A1 (en) 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
EP1830876B1 (en) * 2004-12-30 2015-04-08 Meda AB Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor
WO2006091769A1 (en) 2005-02-24 2006-08-31 Janssen Pharmaceutica N.V. Novel quinoline derivatives as potassium ion channel openers
RU2007141067A (ru) 2005-04-14 2009-05-20 Мерк Патент ГмбХ (DE) Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
JP2008540363A (ja) 2005-05-04 2008-11-20 ノクソン・フアルマ・アクチエンゲゼルシヤフト シュピーゲルマーの新規な使用
EP1896582A4 (en) * 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
WO2007030642A2 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
NZ566982A (en) * 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US20080031887A1 (en) 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
JP2009542645A (ja) 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
RU2483080C2 (ru) 2006-10-27 2013-05-27 Дженентек, Инк. Антитела и иммуноконъюгаты и их применение
CA2673444C (en) 2006-12-21 2015-01-20 F. Hoffmann-La Roche Ag Polymorphs of a mglur5 receptor antagonist
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
EA019151B1 (ru) 2007-02-07 2014-01-30 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Конъюгаты синтетических агонистов tlr и их применение
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
US8436178B2 (en) 2007-05-08 2013-05-07 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
KR20100063048A (ko) 2007-07-31 2010-06-10 더 존스 홉킨스 유니버시티 신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
CA2891005A1 (en) 2007-09-28 2008-10-09 Bind Therapeutics, Inc. Cancer cell targeting using nanoparticles
CN101909624A (zh) 2008-01-15 2010-12-08 麦达股份公司 用咪唑并喹啉衍生物治疗结肠病或预防结肠直肠癌
WO2009093250A2 (en) 2008-01-25 2009-07-30 Gavish-Galilee Bio Applications Ltd Targeting of innate immune response to tumor site
JP2011511073A (ja) 2008-02-07 2011-04-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒ７活性化物質による膀胱の疾患の治療
KR20160125535A (ko) 2008-03-18 2016-10-31 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
WO2010020590A1 (en) 2008-08-20 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
EP2427485B1 (en) 2009-05-07 2016-12-07 ImmunoCellular Therapeutics, Ltd. Cd133 epitopes
WO2010132622A2 (en) 2009-05-14 2010-11-18 The Regents Of The University Of California Anticd20-cpg conjugates and methods of treating b cell malignancies
US20110077263A1 (en) 2009-09-29 2011-03-31 University Of Southern California Methods and Compositions of Toll-Like Receptor (TLR) Agonists
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
WO2011084726A1 (en) 2009-12-21 2011-07-14 3M Innovative Properties Company BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
WO2011084725A1 (en) 2009-12-21 2011-07-14 3M Innovative Properties Company 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
US9169325B2 (en) 2010-04-13 2015-10-27 Celldex Therapeutics, Inc. Antibodies that bind human CD27 and uses thereof
CA2798323A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
RU2013110889A (ru) 2010-08-13 2014-09-20 Бейлор Рисёч Инститьют Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
SG189071A1 (en) 2010-10-01 2013-05-31 Ventirx Pharmaceuticals Inc Therapeutic use of a tlr agonist and combination therapy
RU2013131232A (ru) * 2010-12-09 2015-01-20 Дженентек, Инк. Лечение her2-позитивного рака при помощи паклитаксела и трастузумаба-mсc-dm1
MX348935B (es) 2011-01-12 2017-07-03 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
RU2636029C2 (ru) 2011-02-01 2017-11-17 Генмаб А/С Человеческие антитела и конъюгаты антитело-препарат против cd74
WO2012122396A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
EA034193B1 (ru) 2011-04-21 2020-01-15 Оригенис Гмбх Гетероциклические соединения в качестве ингибиторов киназ
UY34032A (es) 2011-04-21 2012-11-30 Origenis Gmbh Nuevos inhibidores de quinasa
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
US9120763B2 (en) 2011-08-11 2015-09-01 Huntsman Advanced Materials Americas Llc Method for producing benzoxazine compounds
WO2013043647A1 (en) 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
WO2013063280A1 (en) 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN104661683A (zh) 2011-11-09 2015-05-27 埃森德生物制药有限公司 免疫调节缀合物
US9556167B2 (en) * 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
EP2890715B1 (en) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
KR102274722B1 (ko) 2012-08-23 2021-07-09 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체
US9637491B2 (en) 2012-10-19 2017-05-02 Origenis Gmbh Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
EP2787005A1 (en) 2013-04-02 2014-10-08 Activartis Biotech GmbH Targeted cancer immune therapy
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
SG11201605296SA (en) * 2014-01-10 2016-07-28 Birdie Biopharmaceuticals Inc Compounds and compositions for treating her2 positive tumors
US20150374815A1 (en) 2014-06-25 2015-12-31 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
DK3166976T3 (da) 2014-07-09 2022-04-11 Birdie Biopharmaceuticals Inc Anti-pd-l1-kombinationer til behandling af tumorer
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
MY191938A (en) 2015-09-01 2022-07-19 Taiho Pharmaceutical Co Ltd Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
US10821127B2 (en) 2015-11-09 2020-11-03 Shaperon Inc. Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
WO2020051356A1 (en) 2018-09-07 2020-03-12 Birdie Biopharmaceuticals, Inc. Imidazoquinoline compounds and uses thereof
KR20210130139A (ko) 2018-12-26 2021-10-29 버디 바이오파마슈티칼즈, 인크. 암 치료를 위한 면역 조절 조합 및 방법
EP3937939A4 (en) 2019-03-15 2022-12-07 Birdie Biopharmaceuticals Inc. IMMUNOMODULATORY COMBINATIONS AND METHODS OF TREATMENT OF CANCER
CN116056710A (zh) 2020-08-26 2023-05-02 博笛生物科技有限公司 用tlr激动剂治疗癌症

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079924A1 (en) * 2006-12-22 2008-07-03 3M Innovative Properties Company Immune response modifier compositions and methods

Also Published As

Publication number Publication date
US20200276327A1 (en) 2020-09-03
ES2916873T3 (es) 2022-07-06
EP4056594A1 (en) 2022-09-14
US20160375148A1 (en) 2016-12-29
US20180110874A1 (en) 2018-04-26
JP2017507912A (ja) 2017-03-23
US20200353093A1 (en) 2020-11-12
EP3092256B1 (en) 2022-05-18
JP2017502068A (ja) 2017-01-19
CN105899537A (zh) 2016-08-24
AU2015205753A1 (en) 2016-07-21
AU2015205755B2 (en) 2020-05-07
CA2936377A1 (en) 2015-07-16
TW201613648A (en) 2016-04-16
EP3092255A4 (en) 2017-09-20
US10780180B2 (en) 2020-09-22
JP2017503803A (ja) 2017-02-02
US9827329B2 (en) 2017-11-28
US20200155700A1 (en) 2020-05-21
US20160324983A1 (en) 2016-11-10
IL246680A0 (en) 2016-08-31
US10328158B2 (en) 2019-06-25
SG11201605449YA (en) 2016-08-30
TWI691338B (zh) 2020-04-21
WO2015103987A1 (en) 2015-07-16
IL246681A0 (en) 2016-08-31
AU2015205755A1 (en) 2016-07-21
CA2936375A1 (en) 2015-07-16
US20190269789A1 (en) 2019-09-05
US20200345860A1 (en) 2020-11-05
IL246679A0 (en) 2016-08-31
EP3092254A4 (en) 2017-09-20
US10548985B2 (en) 2020-02-04
US20170028079A1 (en) 2017-02-02
WO2015103990A1 (en) 2015-07-16
JP2020114836A (ja) 2020-07-30
US11633495B2 (en) 2023-04-25
EP3092255A1 (en) 2016-11-16
SG11201605296SA (en) 2016-07-28
EP3092256A1 (en) 2016-11-16
US11633494B2 (en) 2023-04-25
DK3092256T3 (da) 2022-06-20
JP6957154B2 (ja) 2021-11-02
CN114671954A (zh) 2022-06-28
CN105899539A (zh) 2016-08-24
US11786604B2 (en) 2023-10-17
US10744206B2 (en) 2020-08-18
TWI691337B (zh) 2020-04-21
TW201613647A (en) 2016-04-16
CN105899538A (zh) 2016-08-24
EP3092254A1 (en) 2016-11-16
EP3092256A4 (en) 2018-05-16
US20190269790A1 (en) 2019-09-05
SG11201605455YA (en) 2016-08-30
WO2015103989A1 (en) 2015-07-16
CN113633783A (zh) 2021-11-12
CN114716555A (zh) 2022-07-08
CA2936376A1 (en) 2015-07-16
TW201611847A (en) 2016-04-01
AU2015205755C1 (en) 2020-08-13
CN105899539B (zh) 2021-11-09
US20230390410A1 (en) 2023-12-07
JP7290332B2 (ja) 2023-06-13
AU2015205756A1 (en) 2016-07-21
JP2022126880A (ja) 2022-08-30

Similar Documents

Publication Publication Date Title
TWI674904B (zh) 用於免疫療法的化合物及組合物
TWI691335B (zh) 用於治療腫瘤的抗pd-l1組合
JP6921745B2 (ja) 腫瘍を治療するための抗ｐｄ−ｌ１コンジュゲート
CN104861067A (zh) 用于免疫疗法的化合物和组合物
HK40080898A (en) Compounds and compositions for immunotherapy

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees